| Autor: |
Zhang, Xiang, Zhong, Yi, Liu, Lixia, Suo, Shanshan, Zhao, Shuqi, Xiao, Feng, Qin, Jiayue, Tong, Hongyan, Jin, Jie, Yu, Wenjuan |
| Předmět: |
|
| Zdroj: |
British Journal of Haematology; Jul2024, Vol. 205 Issue 1, p352-355, 4p |
| Abstrakt: |
This article discusses a case report of a 32-year-old woman with T-cell acute lymphoblastic leukemia (T-ALL) who had the rare genetic aberration MN1:ETV6. The patient initially had a poor response to standard chemotherapy but was found to be significantly sensitive to the BCL-2 inhibitor venetoclax (VEN). The article highlights the molecular features and sensitivity to VEN of MN1:ETV6-positive T-ALL and suggests that targeted therapies like VEN can be beneficial for patients with this genetic abnormality. The study was funded by the Natural Science Foundation of Zhejiang Province and the National Natural Science Foundation of China. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text